$IMMP News

Last published 1d ago

1d agoIMMPImmutep Further Expands United States Patent Estate for Efti-Based Combination TherapiesGlobeNewswireSYDNEY, AUSTRALIA, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapies, today announced the grant of a new patent (number 12,788,796) entitled “ Combined Preparations for the Treatment of Cancer or Infection ” by the United States Patent and Trademark Office (USPTO).
1d agoIMMPImmutep Announces Release of CTOS 2026 Abstract Reporting First Survival Data from EFTISARC-NEOGlobeNewswireSYDNEY, AUSTRALIA, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) today announced the release of an abstract reporting interim disease-free survival data and clinicopathological correlates from EFTISARC-NEO, the investigator-initiated Phase II trial of eftilagimod alfa (efti) plus KEYTRUDA ® (pembrolizumab) and radiotherapy as neoadjuvant treatment for resectable soft t ...
3d agoIMMPIMP761 Late-Breaking Abstract at ACR Convergence 2026 Highlights Statistically Significant & Exposure-Dependent Inhibition of T-Cell-Driven Immune ResponsesGlobeNewswireStatistically significant and exposure-dependent inhibition of T-cell-driven immune responses in healthy volunteers, with greater pharmacodynamic effects at higher IMP761 exposureWell tolerated across all seven dose
3d agoIMMPIMP761 Late-Breaking Abstract at ACR Convergence 2026 Highlights Statistically Significant & Exposure-Dependent Inhibition of T-Cell-Driven Immune ResponsesGlobeNewswireStatistically significant and exposure-dependent inhibition of T-cell-driven immune responses in healthy volunteers, with greater pharmacodynamic effects...
6d agoIMMPImmutep Announces Upcoming Poster Presentations at CTOS 2026 and ESMO Immuno-Oncology & Advanced Therapies Congress 2026GlobeNewswireSYDNEY, AUSTRALIA, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage immunotherapy company targeting cancer and autoimmune
1w agoIMMPImmutep Quarterly Activities Report Q1 FY27GlobeNewswireMedia Release Immutep intends to focus the registration-directed clinical development of efti on HNSCC in patients with CPS <1 and the neoadjuvant setting of STS, with preparations for future clinical trials
2w agoIMMPImmutep Receives A$2.16 million French R&D Tax IncentiveGlobeNewswireSYDNEY, AUSTRALIA, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage immunotherapy company targeting cancer and autoimmune
2w agoIMMPImmutep Announces Presentation of Quality of Life Data from EFTISARC-NEO Phase II Trial at ESMO 2026GlobeNewswireQuality of life remained stable during neoadjuvant treatment with efti, pembrolizumab and radiotherapy, with statistically significant improvement after surgery SYDNEY, AUSTRALIA, Oct. 23, 2026 (GLOBE NEWSWIRE) --
3w agoIMMPImmutep Announces Late-Breaking Abstract on IMP761 Accepted for Poster Presentation at ACR Convergence 2026GlobeNewswire• Late-breaking poster will present data from the first-in-human Phase I study of IMP761, a first-in-class LAG-3 agonist antibody, in healthy volunteers SYDNEY, AUSTRALIA, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Immutep
4w agoIMMPImmutep and Monash University Secure Further ARC Linkage Projects Funding for LAG-3 ResearchGlobeNewswireSYDNEY, AUSTRALIA, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel immunotherapies for
4w agoIMMPImmutep Regains Compliance with Nasdaq Minimum Bid Price RequirementGlobeNewswireSYDNEY, AUSTRALIA, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune diseases,
1mo agoIMMPChange to American Depositary Share RatioGlobeNewswireSYDNEY, AUSTRALIA, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune diseases,
2mo agoIMMPMeet the Manager: Christopher Joye of Coolabah Capital on fixed income opportunities - IMMUTEP LTDEarnings Call TranscriptsKoolaburra runs about $20 billion of global fixed income. We have the largest team in public fixed income in Australia comprising approximately 14 portfolio managers and traders and 22 analysts around the world. In total
3mo agoIMMPImmutep Quarterly Activities Report Q4 FY26GlobeNewswireMedia Release Pooled analysis of five efti trials (presented at ASCO 2026) reinforced efti's mechanism of action, tying immune activation to a 7.7-month median overall survival benefit in biological responders
3mo agoIMMPImmutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026GlobeNewswireSYDNEY, AUSTRALIA, July 24, 2026 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune diseases,
4mo agoIMMPImmutep Secures Fourth United States Patent for Eftilagimod Alfa in Combination with a PD-1 Pathway InhibitorGlobeNewswireSYDNEY, AUSTRALIA, July 14, 2026 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel immunotherapies, today announced the
4mo agoIMMPImmutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004GlobeNewswireINSIGHT-003 demonstrates mature mOS of 30.9 months in both the overall population (N=51) and patients with TPS <50% (N=47) in 1L non-squamous NSCLCOutcomes continue to compare favourably with historical
5mo agoIMMPImmutep to Present Positive Interim Phase I Data for IMP761, a First-in-Class LAG-3 Agonist Antibody, at EULAR 2026GlobeNewswireFirst-in-human Phase I study met its primary endpoint, demonstrating favourable safety and tolerability in healthy volunteers in the single ascending dose part of the studyPhase I data demonstrate statistically
5mo agoIMMPSCHRODERS: ECONOMIC UPDATE | ASX INVESTOR DAY MAY 2026 - IMMUTEP LTDEarnings Call TranscriptsHi, I'm Sebastian Mullins, Head of Multi-Asset and Fixed Income at Schroders Australia. Today I'm going to go through what our view is of the global macroeconomic landscape, and then talk about how that might impact diff
5mo agoIMMPThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 6, 2026 in Immutep Limited Lawsuit - IMMPGlobeNewswireNEW YORK, May 29, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Immutep Limited (NASDAQ:IMMP). Shareholders who purchased shares of IMMP during the class period listed are
5mo agoIMMPSystemic immune activation with eftilagimod alfa associated with statistically significant increased overall survival in late-stage cancer patientsGlobeNewswireSYDNEY, AUSTRALIA, May 28, 2026 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company targeting cancer and autoimmune diseases, today
6mo agoIMMPImmutep Quarterly Activities Report Q3 FY26GlobeNewswireFollowing IDMC recommendation after interim futility analysis the decision was made to discontinue the TACTI-004 Phase III trialRoot cause analysis is ongoing and implications for the broader eftilagimod alfa development
6mo agoIMMPImmutep Receives Nasdaq Notice of Bid Price DeficiencyGlobeNewswireSYDNEY, AUSTRALIA, April 30, 2026 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), advises that it has received a written notification from The Nasdaq Stock Market LLC (Nasdaq)
6mo agoIMMPImmutep Announces Abstract Accepted for Presentation at the American Society of Clinical Oncology (ASCO) 2026 Annual MeetingGlobeNewswireSYDNEY, AUSTRALIA, April 22, 2026 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage immunotherapy company targeting cancer and autoimmune diseases, today
7mo agoIMMPImmutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue SarcomaGlobeNewswireSYDNEY, AUSTRALIA, April 15, 2026 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company targeting cancer and autoimmune diseases, today
8mo agoIMMPTACTI-004 Phase III Study in First Line NSCLC to be discontinued following Futility AnalysisGlobeNewswireIndependent Data Monitoring Committee Recommends Discontinuation of Phase III Trial Following Futility Analysis SYDNEY, AUSTRALIA, March 13, 2026 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep"
9mo agoIMMPImmutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLCGlobeNewswireThe registrational TACTI-004 trial in first line non-small cell lung cancer (1L NSCLC) has enrolled 378 patients globally, 50% of the trial's targeted enrolment Futility analysis and completion of patient enrolment
9mo agoIMMPImmutep Quarterly Activities Report Q2 FY26GlobeNewswireMedia Release Entered into strategic collaboration with Dr. Reddy's for commercialisation of eftilagimod alfa (efti) in all countries outside North America, Europe, Japan, and Greater ChinaIn January 2026, Immutep
10mo agoIMMPImmutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I StudyGlobeNewswireSingle-ascending dose portion of study has successfully completed 2.5 and 7 mg / kg levelsDose dependent immunosuppressive effect against a strong foreign antigen observed with continued favourable safety
11mo agoIMMPImmutep Announces Strong Operational Progress in Global TACTI-004 (KEYNOTE-F91) Phase III and Enrolment Continues at Robust PaceGlobeNewswireThe registrational TACTI-004 Phase III has enrolled 289 patients globally, over 38% of the trial's targeted enrolmentStrong operational progress continues globally with over 120 activated clinical sites and 27 countries
11mo agoIMMP RDYImmutep and Dr. Reddy's enters into Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod AlfaGlobeNewswireDr. Reddy's receives exclusive rights to develop and commercialise Eftilagimod Alfa in all countries outside North America, Europe, Japan, and Greater China Under the terms, Immutep to receive upfront payment of USD 20
11mo agoIMMPImmutep to Present New Data from AIPAC-003 Phase II at the 2025 San Antonio Breast Cancer SymposiumGlobeNewswireImmunotherapy-chemotherapy combination of eftilagimod alfa (efti) and paclitaxel led to strong objective response rates and immune activation in heavily pretreated metastatic breast cancer patientsAIPAC-003 has resulted
12mo agoIMMPTranslational Data and Significant Pathologic Response Rates from EFTISARC-NEO Phase II Highlighted in Oral Presentation at CTOS 2025GlobeNewswireNovel combination with neoadjuvant eftilagimod alfa (efti) achieves significant 51.5% tumour hyalinization/fibrosis across multiple soft tissue sarcoma subtypes including rare and highly aggressive tumours with poor
1y agoIMMPImmutep Receives A$4.6 million R&D Tax Incentive from French GovernmentGlobeNewswireMedia Release SYDNEY, AUSTRALIA, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune
1y agoIMMPImmutep Quarterly Activities Report Q1 FY26GlobeNewswireMedia Release Pivotal TACTI-004 (KEYNOTE-F91) Phase III trial evaluating eftilagimod alfa (efti) in first line non-small cell lung cancer continues to build momentum and is recruiting patients at a growing number of
1y agoIMMPPrimary Endpoint Met in EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma and Data Presented at ESMO Congress 2025GlobeNewswireNovel combination including eftilagimod alfa (efti) in neoadjuvant setting drives 51.5% tumour hyalinization/fibrosis in patients with soft tissue sarcoma (p<0.001) High level of tumour hyalinization/fibrosis,
1y agoIMMPTwo Posters at ESMO Congress 2025 Highlight Immutep's Focus on Changing Treatment Landscape in First Line Non-Small Cell Lung CancerGlobeNewswireNovel combination of efti with KEYTRUDA® and chemotherapy generates strong response rates across all PD-L1 expression levels in first line non-small cell lung cancer (1L NSCLC) including 61.7% ORR in low & no
1y agoIMMPImmutep Announces Successful Completion of FDA Project Optimus RequirementsGlobeNewswireConfirmation of 30mg efti as optimal biological dose relevant for Immutep's oncology pipeline and potential future Biological License Applications (BLA)Registrational TACTI-004 (KEYNOTE-F91) Phase III trial in first line
1y agoIMMPImmutep Announces Update for TACTI-004 (KEYNOTE-F91) Phase III Trial in First Line Non-Small Cell Lung CancerGlobeNewswireGlobal Phase III trial has enrolled and randomised over 170 patients, reaching an important milestone as this is above the amount needed to conduct the futility analysisOver 100 clinical sites across 24 countries now
1y agoIMMPImmutep Announces Research Collaboration with the George Washington University Cancer Center to Evaluate Neoadjuvant EftiGlobeNewswireGW Cancer Center to initiate Phase II trial evaluating neoadjuvant efti as monotherapy and in combination with chemotherapy prior to surgery in HR+/HER2-neg breast cancer patientsSecond investigator-initiated trial to
1y agoIMMPImmutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025GlobeNewswireData to be presented in the Immunotherapy & Cell Therapy in Sarcoma: Emerging Frontiers session at the Connective Tissue Oncology Society (CTOS) 2025 Annual Meeting SYDNEY, AUSTRALIA, Sept. 08, 2025 (GLOBE
1y agoIMMPImmutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alfa in Head and Neck Cancer with CPS <1GlobeNewswireSYDNEY, AUSTRALIA, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces
1y agoIMMPImmutep Quarterly Activities Report Q4 FY25GlobeNewswireMedia Release The pivotal TACTI-004 Phase III trial in first line non-small cell lung cancer (1L NSCLC) continues to build momentum and is recruiting patients at a growing number of activated clinical sites and
1y agoIMMPImmutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung CancerGlobeNewswireSYDNEY, AUSTRALIA, July 29, 2025 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces
1y agoIMMPImmutep Announces Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025GlobeNewswireSYDNEY, AUSTRALIA, July 28, 2025 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces
1y agoIMMPImmutep's Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue SarcomaGlobeNewswireNovel combination with efti has met the trial's primary endpoint of tumour hyalinization/fibrosis in the neoadjuvant setting for patients with resectable soft tissue sarcomaDetailed results are planned for presentation
1y agoIMMPImmutep's Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung CancerGlobeNewswireNovel combination achieves 60.8% response rate and 90.2% disease control rate in first-line non-small cell lung cancer (1L NSCLC)Notably, ~92% of all evaluable patients have PD-L1 TPS <50%, including 43% with PD-L1
1y agoIMMPImmutep's Efti in Combination with KEYTRUDA® (pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer with CPS <1GlobeNewswireComplementary nature of these two immunotherapies leads to excellent 17.6-month median Overall Survival in head and neck cancer patients with PD-L1 CPS <1Mature overall survival data builds on encouraging high
1y agoIMMPImmutep Quarterly Activities Report Q3 FY25GlobeNewswireMedia Release First patient safely dosed in TACTI-004 Phase III lung cancer trial, marking a significant milestonePivotal TACTI-004 trial design presented at the European Lung Cancer Congress (ELCC) 2025Patient
1y agoIMMPImmutep to Participate in Upcoming Investor ConferencesGlobeNewswireSYDNEY, AUSTRALIA , April 02, 2025 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today